Glancy Donovan Michael 4

What Happened Glancy Donovan Michael, a director of Collegium Pharmaceutical, was awarded 17,482 restricted stock units (RSUs) on 2026-05-14 (reported on Form 4 filed 2026-05-18). The grant is reported as an award (code A) with no purchase price ($0) because RSUs are a form of equity compensation that convert into common shares upon vesting.

Key Details

• Transaction date: 2026-05-14; Form 4 filed: 2026-05-18 (appears timely under the two-business-day rule).
• Award type and size: 17,482 RSUs granted (reported acquisition = 17,482 shares at $0.00).
• Vesting schedule (footnote): 8,741 RSUs vest on the earlier of May 14, 2027 or the Issuer’s 2027 Annual Meeting; the other 8,741 RSUs vest on May 14, 2027 — both subject to continued service.
• Settlement: RSUs will be settled in shares on the vesting dates, or earlier at the director’s election upon end of service, death/disability, or a change in control.
• Shares owned after transaction: not disclosed in the provided filing.

Context RSU grants are standard compensation for directors and are not an open-market purchase or sale. They represent a right to receive common stock in the future (one RSU = one share on settlement). This award does not itself indicate buying or selling pressure; any market impact would occur only when RSUs vest and shares are issued or sold.